Labriola, Dominic

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 2,084

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Harrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023) · Nature Medicine

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 435

OS-124 Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH

Harrison, S. A., Taub, R., Labriola, D., Zhang, H., Chng, E., Ren, Y., Tai, D., & Schattenberg, J. M. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Cited by 3

SAT-214 Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)

Schattenberg, J. M., Anstee, Q. M., Harrison, S. A., Noureddin, M., Taub, R., Labriola, D., Priel, J., & Padmanabhan, K. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Cited by 1